## Therese Mulvey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5919690/publications.pdf

Version: 2024-02-01

1478505 1474206 1,576 9 9 6 citations h-index g-index papers 9 9 9 2331 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. Journal of Clinical Oncology, 2015, 33, 2563-2577.	1.6	783
2	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. Journal of Clinical Oncology, 2016, 34, 2925-2934.	1.6	538
3	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of Clinical Oncology, 2021, 39, 2375-2385.	1.6	76
4	Telehealth in Oncology: ASCO Standards and Practice Recommendations. JCO Oncology Practice, 2021, 17, 546-564.	2.9	73
5	Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. Journal of Clinical Oncology, 2021, 39, 1165-1184.	1.6	54
6	Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, , 1-8.	4.9	36
7	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18.	5.2	8
8	Associations of baseline patientâ€reported outcomes with treatment outcomes in advanced gastrointestinal cancer. Cancer, 2021, 127, 619-627.	4.1	7
9	Abstract P1-14-02: Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER, part 1). Cancer Research, 2022, 82, P1-14-02-P1-14-02.	0.9	1